Fibroblast growth factor-23 (FGF-23) / soluble Klotho protein (sKlotho) / sclerostin glycoprotein ratio disturbance is a novel risk factor for cardiovascular complications in ESRD patients receiving treatment with regular hemodialysis or hemodiafiltration
- Authors: Milovanova LY.1, Dobrosmyslov IA1, Milovanov Y.S1, Fomin VV1, Taranova MV1, Kozlov VV1, Milovanova SY.1, Kozevnikova EI1
-
Affiliations:
- I.M. Sechenov First Moscow State Medical University, Ministry of Health (Sechenov University)
- Issue: Vol 90, No 6 (2018)
- Pages: 48-54
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/32765
- DOI: https://doi.org/10.26442/terarkh201890648-54
- ID: 32765
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
L Yu Milovanova
I.M. Sechenov First Moscow State Medical University, Ministry of Health (Sechenov University)
Email: Ludm.milovanova@gmail.com
к.м.н., доц. каф. внутренних, профессиональных болезней и пульмонологии Moscow, Russia
I A Dobrosmyslov
I.M. Sechenov First Moscow State Medical University, Ministry of Health (Sechenov University)зав. отд-нием «Искусственная почка» Университетской клинической больницы №3 Moscow, Russia
Yu S Milovanov
I.M. Sechenov First Moscow State Medical University, Ministry of Health (Sechenov University)д.м.н., проф. каф. внутренних, профессиональных болезней и пульмонологии Moscow, Russia
V V Fomin
I.M. Sechenov First Moscow State Medical University, Ministry of Health (Sechenov University)д.м.н., проф. каф. факультетской терапии №1 Moscow, Russia
M V Taranova
I.M. Sechenov First Moscow State Medical University, Ministry of Health (Sechenov University)к.м.н., доц. каф. внутренних, профессиональных болезней и пульмонологии Moscow, Russia
V V Kozlov
I.M. Sechenov First Moscow State Medical University, Ministry of Health (Sechenov University)к.м.н., доц. каф. общественного здоровья и здравоохранения Moscow, Russia
S Yu Milovanova
I.M. Sechenov First Moscow State Medical University, Ministry of Health (Sechenov University)д.м.н., в.н.с. НИО здоровьесберегающих технологий Научно-технологического парка биомедицины Moscow, Russia
E I Kozevnikova
I.M. Sechenov First Moscow State Medical University, Ministry of Health (Sechenov University)аспирант каф. внутренних, профессиональных болезней и пульмонологии Moscow, Russia
References
- Go A.S, Chertow G.M, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296-305.
- Kumar S, Bogle R, Banerjee D. Why do young people with chronic kidney disease die early? World J Nephrol. 2014;3(4):143-55. doi: 10. 5527/wjn.v3.i4.143
- Milovanova L, Plotnikova A.Phosphorus and Calcium Metabolism Disorders Assosiated with Chronic Kidney Disease Stage III-IV (Systematic Rewiew and Meta-Analysis). In: Manisha Sahay, editor. Chronic Kidney Disease and Renal Transplantation. INTECH; 2012. P. 95-118.
- Milovanova L, Fomin V.V, Mukhin N.A. Nutritional status disorders in Chronic Kidney Disease: practical aspects. In: Chronic Kidney Disease. INTECH; 2017. P. 95-118. ISBN 978-953-51-5463-1.
- Gutierrez O, Mannstadt M, Isakova T, et al. Fibroblast Growth Factor 23 and Mortality among Hemodialysis Patients. N Engl J Med. 2008;359:584-92.
- Seifert M.E, Hruska K.A. The Kidney-Vascular-Bone Axis in the Chronic Kidney Disease-Mineral Bone Disorder. Transplantation. 2016;100(3): 497-505. doi: 10.1097/TP.0000000000000903
- Milovanova L.Yu, Milovanov Yu.S, Kudryavtseva (Kryukova) D.V, Markina M.M, Milovanova S.Yu, Lebedeva M.V, Beketov D.V, Moiseev S.V, Kozlovskaya L.V, Mukhin N.A, Fomin V.V. The role of morphogenetic proteins (fibroblast growth factor - 23 - FGF-23, Klotho) and glycoprotein sclerostin in assessing cardiovascular risk and the prognosis of chronic kidney disease. Terapevticheskiy Arhiv. 2015;(4):46-54.
- Isakova T, Wahl P, Vargas G.S, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011;79:1370-8.
- Hu M.C, Shiizaki K, Kuroo M, et al. Fibroblast Growth Factor 23 and Klotho: Physiology and Pathophysiology of an Endocrine Network of Mineral Metabolism. Annu Rev Physiol. 2013;75:503-33. doi: 10.1146/ annurev-physiol-030212-183727
- Semba R.D, Cappola A.R, Sun K, et al. Plasma klotho and mortality risk in older community - dwelling adults. J Gerontol A Biol Sci Med Sci. 2011;66:794-800.
- Donate-Correa J, Martín-Núñez E, Mora-Fernández C, et al. Klotho in cardiovascular disease: Current and future perspectives. World J Biol Chem. 2015;6(4):351-7. doi: 10.4331/wjbc.v6.i4.351
- Cejka D, Herberth J, Branscum A.J, Fardo D.W, Monier-Faugere M.C, Diarra D, et al. Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol. 2011;6:877-82. doi: 10.2215/CJN.06550810
- Lips L, de Roij van Zuijdewijn C.L.M, ter Wee P.M, Bots M.L, Blankestijn P.J, van den Dorpel M.A, Fouque D, de Jongh R, Pelletier S, Vervloet M.G. Serum sclerostin: relation with mortality and impact of hemodiafiltration. Nephrol Dial Transplant. 2017;32(7):1217-23. doi: 10.1093/ndt/gfw246
- Milovanova L, Fomin V.V, Lysenko (Kozlovskaya) L.V. Disorders in the System of Mineral and Bone Metabolism Regulators - FGF-23, Klotho and Sclerostin - in Chronic Kidney Disease: Clinical Significance and Possibilities for Correction. In: Chronic Kidney Disease. INTECH; 2017. ISBN 978-953-51-5463-1
- Grabner A, Amaral A.P, Schramm K, et al. Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy. Cell Metab. 2015;22(6):1020-32. doi: 10.1016/j.cmet. 2015.09. 002
- Di Marco G.S, Reuter S, Kentrup D, Grabner A, Amaral A.P, Fobker M, Stypmann J, Pavenstadt H, Wolf M, Faul C, Brand M.Treatment of established left ventricular hypertrophy with fibroblast growth factor receptor blockade in an animal model of CKD. Nephrol Dial Transplant. 2014;10:1-8.
- Smith K, Defilippi C, Isakova T, Gutiérrez O.M, Laliberte K Seliger S, Kelley W, Duh S.H, Hise M, Christenson R, Wolf M. Fibroblast growth factor-23, high - sensitivity cardiac troponin, and left ventricular hypertrophy in CKD. J Am Kidney Dis. 2013;61(1):67-73.
- Hu M.C, Shi M, Zhang J, et al. Klotho Deficiency Causes Vascular Calcification in Chronic Kidney Disease. J Am Soc Nephrol. 2011;22(1):124-36. doi: 10.1681/ASN.2009121311
- Bruzzese A, Lacquaniti A, Cernaro V, Ricciardi C.A, Loddo S, Romeo A. Sclerostin levels in uremic patients: a link between bone and vascular disease. J Renal Failure. 2016;38(5):123-9.
- Kanbay M, Solak Y, Siriopol D, Aslan G, Afsar B, Yazici D, Covic A. Sclerostin, cardiovascular disease and mortality: a systematic review and meta - analysis. Int Urol Nephrol. 2016;48(12):2029-42.
- Register T.C, Hruska K.A, Divers J, Bowden D.W, Palmer N.D, Carr J.J, et al. Sclerostin is positively associated with bone mineral density in men and women and negatively associated with carotid calcified atherosclerotic plaque in men from the African American-Diabetes Heart Study. J Clin Endocrinol Metab. 2013 Epub 2013.11.02. doi: 10.1210/ jc.2013-3168